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Abstract
Background: Abnormal proliferation, apoptosis, migration and contraction of airway smooth muscle (ASM) cells in
airway remodeling in asthma are basically excessive repair responses to a network of inflammatory mediators such
as PDGF, but the mechanisms of such responses remain unclear. Nogo-B, a member of the reticulum family
4(RTN4), is known to play a key role in arteriogenesis and tissue repair. Further studies are needed to elucidate the
role of Nogo-B in airway smooth muscle abnormalities.
Methods: A mouse model of chronic asthma was established by repeated OVA inhalation and subjected to Nogo-B
expression analysis using immunohistochemistry and Western Blotting. Then, primary human bronchial smooth
muscle cells (HBSMCs) were cultured in vitro and a siRNA interference was performed to knockdown the expression
of Nogo-B in the cells. The effects of Nogo-B inhibition on PDGF-induced HBSMCs proliferation, migration and
contraction were evaluated. Finally, a proteomic analysis was conducted to unveil the underlying mechanisms
responsible for the function of Nogo-B.
Results: Total Nogo-B expression was approximately 3.08-fold lower in chronic asthmatic mice compared to naïve
mice, which was obvious in the smooth muscle layer of the airways. Interference of Nogo-B expression by siRNA
resulted nearly 96% reduction in mRNA in cultured HBSMCs. In addition, knockdown of Nogo-B using specific
siRNA significantly decreased PDGF-induced migration of HBSMCs by 2.3-fold, and increased the cellular
contraction by 16% compared to negative controls, but had limited effects on PDGF-induced proliferation.
Furthermore, using proteomic analysis, we demonstrate that the expression of actin related protein 2/3 complex
subunit 5 (ARPC 2/3) decreased and, myosin regulatory light chain 9 isoform a (MYL-9) increased after Nogo-B
knockdown.
Conclusions: These data define a novel role for Nogo-B in airway remodeling in chronic asthma. Endogenous
Nogo-B, which may exert its effects through ARPC 2/3 and MYL-9, is necessary for the migration and contraction
of airway smooth muscle cells.
Background
Airway remodeling in chronic asthma is characterized
by epithelial detachment, subepithelial fibrosis, mucus
hyperplasia, angiogenesis, airway edema, changes in the
cartilage, and most obviously, an increase in airway
smooth muscle mass. It is believed that abnormalities in
proliferation, apoptosis, migration, secretion, and con-
traction of smooth muscle cells (SMCs) all play roles in
airway smooth muscle remodeling, and contribute to
airway hyperresponsiveness [1,2].
The cause for such abnormalities is complex and
depends on a network of inflammatory mediators and
cytokines. The levels of some mediators, such as PDGF
and TGF-b, are greatly elevated in the lung of asthmatic
patient and are thought to play important roles in airway
smooth muscle remodeling [3,4]. In vitro studies have
shown that PDGF is a potent SMC mitogen that can pro-
mote proliferation and migration while switching cells to
an “immature” phenotype and, therefore, decreasing the
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any medium, provided the original work is properly cited.contractility of the cells. However, the precise mechan-
isms underlying these processes remain unclear [5,6].
Reticulons (RTNs) are a family of proteins that include
four family members, RTN 1, 2, 3, and 4. In mammals,
the RTNs are mainly localized to the endoplasmic reticu-
lum (ER) and are involved in tubulogenesis of the ER and
membrane curvature [7,8]. Different isoforms of the RTN
family have distinct functions. Recently, the RTN 4 iso-
forms, also called Nogo, have been demonstrated to be
vital mediators of a variety of cellular responses and tis-
sue repair. The RTN 4 family is expressed in three splice
variants including Nogo-A, -B, and -C. Nogo-A is pri-
marily expressed in the central nervous system and is
identified as a potent inhibitor of axonal growth and
repair [9]. Nogo-C exists mainly in skeletal muscle,
whereas Nogo-B is widely expressed in peripheral tissues
including those of lung and vascular systems [10]. Mice
deficient in Nogo-B exhibited an exaggerated neointimal
proliferation that could be rescued by adenoviral-
mediated gene transfer of Nogo-B [11]. In addition,
Nogo-B is necessary for modulating macrophage infiltra-
tion and expressing inflammatory mediators macrophage
infiltrating and inflammatory mediators’ expression for
tissue repair after ischemic injury. All of these factors
observations indicate that Nogo-B plays a pivotal role in
vascular remodeling and tissue repair [12]. Airway
smooth muscle remodeling in asthma is basically a SMC
repair response to inflammatory mediates and cytokines,
the role of Nogo-B in the process of airway smooth mus-
cle remodeling has not yet been reported.
We evaluated the role of Nogo-B in ASM in a mouse
model of chronic asthma and then determined the
effects of Nogo-B on PDGF-induced proliferation,
migration and contraction of HBSMCs in vitro using a
siRNA strategy. Proteomic analysis was then performed
to unveil the underlying mechanisms. Our results
demonstrate a novel mechanism through which Nogo-B
regulates airway smooth muscle cells.
Materials and methods
Animal models
Four to six-week-old male BALB/c mice (Shanghai
Laboratory Animal Company, Shanghai, China) were
used in our experiments. The mice were sensitized intra-
peritoneally with Ovalbumin (OVA, Sigma Aldrich) in
alum (Days 0, 7, and 14). Control mice received the same
volume of PBS in alum, as previously described [13].
Chronic allergic airway remodeling was induced when
mice were subsequently exposed to aerosolized OVA
challenges three times a week from Days 21 to 72. Mice
were sacrificed at the indicated times and the lungs were
harvested, either into 4% formalin for histological evalua-
tion or snap-frozen into liquid nitrogen for protein
preparations. Animals were treated humanely according
to Institutional Animal Care procedures.
Cell culture
Primary human bronchial smooth muscle cells (HBSMCs)
and smooth muscle growth medium (SmGM) were pur-
chased from ScienCell (U.S.A). HBSMCs were cultured in
SmGM containing 5% FBS. The cells were incubated at
37°C in a 5% CO2-humidified atmosphere. Cells from pas-
sages 4 to 10 were used for the experiment. PDGF-BB was
purchased from R&D (U.S.A) and dissolved in PBS to
yield a stock solution of 1 μg/ml.
Histological examination
Mouse lung tissues were collected and embedded in
paraffin for histological analysis. Lung sections were
stained with hemotoxylin and eosin (H-E) for examina-
tion of airway remodeling. For the immunohistochemis-
try, 5 μm thick sections were cut, and the Envision
method was performed according to the instructions
(DakoCytomation, Denmark). Anti-SM-22 antibody,
anti-Nogo-B antibody were applied. 3, 3’-Diaminobenzi-
dine was used as a chromogen with a subsequent hema-
toxylin counter-stain.
RNA interference
For Nogo-B knockdown, Nogo-B siRNA1 (NOGOi-1 for-
ward: AGA AAU UAU UAA UUA CAA A, reverse: UUU
GUA AUU AAU AAU UUC U) and Nogo-B siRNA2
(NOGOi-2 forward: GAU CGU UGU UAG AUC UUU
A, reverse: UAA AGA UCU AAC AAC GAU C) were
employed. The control siRNA in experiments refers to a
negative control siRNA (NEGi forward: UUC UCC GAA
CGU GUC ACG U, reverse: ACG UGA CAC GUU CGG
AGA A). All of the above siRNAs were designed and
synthesized by Qiagen (Germany). For 6-well plate trans-
fection, human bronchial smooth muscle cells were
transfected with 300 ng siRNA using 12 μl Hiperfect
(Qiagen) according to the manufacturers’ instructions.
Efficacy of siRNA interference of Nogo-B was assayed at
24 to -60 h post-transfection by Western blotting.
Western blotting analysis
The protein concentration was determined using the
Bio-Rad protein assay system. HBSMCs were dissolved
and boiled in Laemmli buffer for 5 min. Twenty micro-
grams of proteins were subjected to electrophoresis in
12% SDS-PAGE, transferred to nitrocellulose membrane,
blocked in PBS containing 5% skimmed milk for 2 h at
room temperature and then reacted with the primary
antibody of Nogo-B, ARPC 2/3 (Abcam, Britain) or
MYL-9 (Santa Cruz, U.S.A). The quantity of expressed
protein was normalized to GAPDH.
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Real-time PCR analysis was performed using the Light-
Cycler
® 2.0 Real-Time PCR system (Roche, Switzerland)
and the SYBR PrimeScriptTM RT Reagent Kit (TaKaRa,
Japan) following the manufactures’ instructions. The pri-
mers and reaction conditions were shown as below:
Nogo-B, forward (5’-GCA GGG GCT CCG GCT CAG
TG-3’) and reverse (5’-GTT CAC ATG ACC AAG AGC
CAG-3’);b-actin, forward (5’-GGA CTT CGA GCA
AGA GAT GG-3’) and reverse (5’-AGC ACT GTG
TTG GCG TAC AG-3’), 40 cycles. The Nogo-B mRNA
expression was normalized by the housekeeping gene
b-actin.
Proliferation assay
Cell proliferation assays were performed using Cell
CountingKit-8 (Dojindo, Japan). Cells were plated in
96-well plates at 3.5×10
3 cells per well and cultured in
growth medium with 2% FBS. At the indicated time
points (24 h, and 48 h,), the cell numbers in triplicate
wells were measured as the absorbance at 450 nm from
WST-8(2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-
5-(2,4-disulfophenyl)-2H-tetrazolium, monosodium salt)
Boyden chamber migration
Cell migration assays were performed using Millicell cell
culture inserts (Millipore, U.S.A) [14]. HBSMCs, which
had been treated with siRNA for 48 h, were serum-
starved overnight. PDGF-BB (20 ng/ml) and 10% FBS
were prepared in SmGM and added to the bottom cham-
bers. HBSMCs (5×10
4) in serum free SmGM were added
to the upper chambers. After 5 h of incubation at 37°C,
cells on both sides of the membrane were fixed and
stained with 0.1% crystal violet. Cells on the upper side of
the membrane were removed with a cotton swab. The
average number of cells per field was determined by
counting the number of cells in four high-power (×200)
fields from the lower side of the membrane.
Gel contraction assay
The contractility of the cultured HBSMCs was examined
using a gel contraction assay [15]. For each 6-well plate,
collagen solution was prepared by mixing 450 μlo fi c e -
cold type I collagen (5 mg/ml, Shengyou biotechnology,
China) with 53 μl 10× PBS, pH was adjusted to 7.4 with
0.1 M NaOH. HBSMCs pretreated with siRNA for 48 h
were seeded at a density of 3×10
5 cells/ml; 1.5 ml of gel
suspension was poured into a 6-well culture pate. The
gels were cultured in 2 ml of 5% FBS SmGM overnight
added with PDGF or PBS and then started the contrac-
tion assay. Gel surface images were captured with a digi-
tal camera 24 h later. Contraction of the gel was then
evaluated by measuring its surface area with Image-Pro
Plus 6.0 (Media Cybernetics, Inc. U.S.A). Data were
expressed as percentage of the original gel size.
Proteomic analysis
Proteomic analysis was performed, as previously
described [16]. Briefly, HBSMCs transfected with NEGi
or NOGOi-2 from three 60 mm cell culture dishes were,
respectively, pooled as one sample. Total proteins of the
cell samples were homogenized and treated with 2-D
Clean-Up Kit (Amersham), following the manufacturer’s
protocol. Protein (600 μg) from each sample was loaded
into DryStripTM (13 cm, pH 3-10; Amersham) and iso-
electric focusing was performed on MultiphorTMII
(Amersham) at 18°C. Two 15-min equilibration steps
were carried out using equilibration tubes. After equili-
bration, the strips were transferred onto 15% polyacryla-
mide gels for second dimensional (2D) SDS-PAGE. The
2ndD gels were silver stained and digitized using an ima-
ging system - ChemiImagerTM 5500 (Alpha Innotech,
San Leandro, USA). Image analysis was conducted using
the ImageMasterTM 5.0 (Amersham). Only significantly
different spots (three-fold increase or decrease) were
selected for analysis by mass spectrometry. Target pro-
teins were excised and digested. Peptides were then
extracted, dried and subjected to MALDI-TOF MS analy-
sis. Data from MALDI-TOFMSM Sw e r ea n a l y z e du s i n g
MASCOT (Matrix Science, London) search software.
The following parameters were used in the search: mam-
malian, protein molecular mass ranged from 700 to 32,
000Da, trypsin digest with one missing cleavage, peptide
tolerance of 0.2, MS/MS tolerance of 0.6 Da and possible
oxidation of methionine.
Statistical analysis
All values were expressed as the mean ± SD of n obser-
vations (n > = 3).Statistical analyses between groups
were performed using one-way analysis of variance or
Student t tests between two groups, as appropriate. P <
0.05 was considered statistically significant.
Results
Down-regulation of Nogo-B in airway smooth muscle of
chronic asthmatic mice
To investigate the role of Nogo-B in airway remodeling
in asthma, we constructed a mouse model of chronic
asthma. Evident airway inflammation and airway thick-
ening could be observed in mice with chronic asthma
(Figure 1A-B). The asthmatic mice also had significantly
increased expression of SM-22 (Figure 1C-D), a specific
marker of differentiated ASM cells in the airway, indi-
cating evidence of airway smooth muscle remodeling.
Immunohistochemistry revealed that Nogo-B was widely
expressed in the lung, especially abundant in epithelium,
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In chronic asthmatic mice, the distribution of Nogo-B
was not altered. However, there was a significant decrease
in the airway smooth muscle layer (Figure 1E-F). Addi-
tionally, Realtime analysis revealed a significant reduction
of lung Nogo-B mRNA expression in chronic asthmatic
mice (Figure 1G), in accordance with this, Western blot-
ting analysis of the total proteins collected from the lung
homogenates showed that Nogo-B expression was
approximately 3.08-fold lower in chronic asthmatic mice
than in control mice (Figure 1H-I), indicating that Nogo-B
m a yp l a yar o l ei na i r w a ys m o o t hm u s c l er e m o d e l i n gi n
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Figure 1 Down-regulation of Nogo-B in airway smooth muscle of chronic asthmatic mice. Repeated sensitization and provocation resulted
in airway remodeling (B) compared to wild type littermates (A). Immunohistochemistry analysis demonstrated increased expression of SM-22 in
chronic asthmatic mice (D) relative to wild type littermates(C). Arrow head indicated SM-22 expression in the smooth muscle layer of the
airways. Nogo-B expression in control (E) and chronic asthmatic mice (F). Arrow indicates that Nogo-B expression was lower in the smooth
muscle layer in chronic asthmatic mice than that in control mice. Original magnification: ×100 for the large pictures and ×400 for the smaller
inserts located in the right bottom of the large ones. G, mRNA expression of Nogo-B in the lung of control and chronic asthmatic mouse model.
H, Western blot analysis demonstrated expression of Nogo-B in the lung of controls and chronic asthmatic mice. I, Protein intensity detected by
Western blot with Nogo-B antibody and GAPDH. J, Effects of PDGF on Nogo-B expression in vitro. Data are mean ± SD, n = 7, *P < 0.05 as
indicated.
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an increasing concentration of PDGF-BB for up to 48 h
resulted no obvious change of Nogo-B as evidenced by
western blotting analysis (Figure 1J).
RNAi for Nogo-B expression
To determine the role of Nogo-B in airway smooth mus-
cle cells, we used a siRNA approach to knockdown
Nogo-B expression in HBSMCs in vitro. Transfection of
cells with two different Nogo-B siRNA (NOGOi)
sequences resulted in knock-down of Nogo-B protein
expression, as determined by Western blotting analysis
(Figure 2A). Transfection of negative control siRNA
(NEGi) had no effect on Nogo-B expression levels. Addi-
tionally, NOGOi-transfected cells showed a 96% reduc-
tion in Nogo-B mRNA compared to NEGi-transfected
cells 60 h post-transfection, as determined by quantita-
tive real-time PCR (Figure 2B).
Effects of Nogo-B on proliferation and migration of
HBSMCs
In the next step, we examined the effects of Nogo-B on
PDGF-induced abnormalities of HBSMCs in vitro.
HBSMCs, pretreated with either NEGi or NOGOi-2 for
48 h, were starved overnight, reseeded onto a 96-well
plate at a density of 3.5 × 10
3 in 2% FBS SmGM and
incubated with PDGF-BB (20 ng/ml). Stimulation of
HBSMCs with PDGF for 24 h and 48 h resulted in signif-
icant increase in cell numbers, both in untransfected and
transfected cells, but there was no significant difference
between the NEGi and the NOGOi-2 treated groups.
These results demonstrated that down-regulation of
Nogo-B had no significant effect on the proliferation of
HBSMCs at either time point (Figure 3A). Next, we char-
acterized the effects of Nogo-B on PDGF-induced
HBSMC migration. As shown in Figure 3B, PDGF
(20 ng/ml) resulted in an approximately 4.4-fold increase
in migration of HBSMCs. Also, cells pretreated with
NEGi for 60 h showed a marked increase in migration
after PDGF induction, similar to the untreated controls.
Knockdown of Nogo-B significantly inhibited the migra-
tion of HBSMCs, as much as 2.3-fold compared to the
NEGi group. These findings suggest that Nogo-B is
necessary for the migration of HBSMCs.
Effects of Nogo-B on the contraction of HBSMCs
It is believed that PDGF can switch SMC to an undiffer-
entiated phenotype that exhibits diminished contractility.
Therefore, using a gel contraction assay, we tested the
role of Nogo-B on the contraction of HBSMCs pretreated
with PDGF. Cells pretreated with PDGF (20 ng/ml)
exhibited reduced contractility in NEGi controls and the
untreated controls, as identified from gel surface area. In
the NOGOi-2 group, however, the gel surface was much
smaller than in the NEGi controls and untreated con-
trols, indicating an increased contractility after Nogo-B
down-regulation (Figure 3C-G).
Proteomic analysis revealed changes in MYL-9 and
ARPC2/3 after Nogo-B knock-down
To more clearly define the role of Nogo-B on the modula-
tion of PDGF-induced SMC migration and contraction,
we performed a proteomic analysis. Two-dimensional
electrophoresis was performed and approximately 1,000
spots, on average, were detected for NEGi or NOGOi-2
treated HBSMCs in silver-stained gels using ImageMaster.
Figure 2 Nogo-B was specifically targeted by two Nogo-B small interference RNA (siRNA) sequences. Cells were transfected with 10 nM
Nogo-B siRNA. Following transfection, cells were lysed for Western blot analysis at 24 and 60 h (A) or for RNA isolation at 60 h and real-time
PCR analysis (B). n = 3, *P < 0.05, **P < 0.01 compared with NEGi.
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2D gels could not be separated clearly. In a low molecular
weight region, a mean of 350 spots were matched. In com-
parison with the control group, 15 spots in the NOGOi-2
HBSMC group demonstrated a relative concentration
changed of more than 3-fold. Enlarged silver-stained
gels highlight the quantitative differences in the images
(Figure 4A), here, only the successfully identified spots are
shown). Numbered spots were excised and subjected to
in-gel digestion. Protein identifications, as obtained by
MALDI-TOF MS, are listed in Table 1. We focused our
interests on two of the six proteins successfully identified,
including myosin regulatory light chain 9 isoform a (MYL-
9) and actin related protein 2/3 complex subunit 5 (ARPC
2/3), which, are the key proteins in the processed of SMC
contraction and migration. To further validate the proteo-
mic data, we again performed RNAi in the HBSMCs and
analyzed the protein expression by Western blotting. In
accordance with the results found in the proteomic analy-
sis, Figure 4B demonstrates that the expression of ARPC
2/3 decreased, while MYL-9 expression increased after
Nogo-B knock-down. These results convinced us that the
expression of ARPC 2/3 and MYL-9 changes after Nogo-B
knock-down.
Discussion
In the present study, we showed that Nogo-B was
down-regulated in the smooth muscle layers of the air-
ways of chronic asthmatic mice. In addition, the endo-
genous expression of Nogo-B was necessary for airway
A B
G
CD
EF
Figure 3 Effects of Nogo-B knock-down on proliferation, migration and contraction of HBSMCs. A, Untransfected cells or HBSMCs
transfected with NEGi or NOGOi-2 for 48 h were starved overnight to achieve growth arrestment and treated with PDGF-BB (20 ng/ml). Cell
numbers were counted by proliferation assay. *P < 0.05 compared with untreated control. B, Untransfected cells or HBSMCs transfected with
NEGi or NOGOi-2 for 48 hours were starved overnight a treated with PDGF-BB (20 ng/ml) in SmGM to induce migration. C-F, representative
pictures of contraction of untreated HBSMCs (C) or PDGF-treated untransfected control (D), NEGi transfected (E), and NOGOi-2 transfected
(F) HBSMCs. G, Statistic analysis of the effects of Nogo-B inhibition on the contraction of HBSMsC. All data are mean ± SD, n = 3 for triplicate
experiments, *P < 0.05, **P < 0.01 as indicated.
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limited effect on proliferation of the cells. Furthermore,
we revealed for the first time that ARPC 2/3 and MYL-
9 may be two of the factors responsible for the func-
tional effects of Nogo-B on airway smooth muscle cells.
Our results suggest that Nogo-B plays an important role
in regulating airway smooth muscle cells and, therefore,
participates in airway remodeling in asthma.
We demonstrated that Nogo-B was significantly
down-regulated in the lungs of chronic asthmatic mice.
Also, immunohistochemistry indicated that expression
of Nogo-B decreased in the airways of smooth muscle
layer of chronic asthmatic mice. These results strongly
implicate Nogo-B in asthmatic airway smooth muscle
remodeling. Nogo-B is a 37 kDa protein belonging to
the RTN4 family. The importance of Nogo-A as a
potent inhibitor was initially described during axonal
growth in the central nervous system [9,11,16,17].
Nogo-B, which shares homology with Nogo-A, was then
identified outside the central nervous system [10]. Pre-
vious studies have shown that down-regulation of Nogo-
B most likely occurs under conditions of trauma and
inflammation and, therefore, is responsible for multiple
pathological conditions such as atherosclerosis, aortic
aneurysms formation, and vascular regeneration after
vessel injury [11,18-21]. However, up-regulation of
Figure 4 Identification and verification of changes in proteins expression after Nogo-B knockdown by proteomic assay. A,
Enlargements of silver-stained gels. Representative areas of 2-dimensional gel from NEGi and NOGOi-2 lysates highlighting the quantitative
differences in the images. B, expression of ARPC 2/3 and MYL-9 proteins as detected by Western blot after Nogo-B knockdown (in agreement
with the proteomic findings). This verification experiment was repeated for three times.
Table 1 Identification of the differentially expressed protein after Nogo-B knock-down
No Protein Mr PI Accession No of NCBI Fold Change Sequence Coverage/Score
1 fatty acid binding protein 5 15155 6.6 gi|4557581 3.32 ↓ 31%/199
2 ubiquitin-conjugating enzyme E2N 17127 6.13 gi|4507793 4.22 ↓ 82%/342
3 myosin regulatory light chain 9 isoform a 19814 4.8 gi|29568111 8.05 ↑ 51%/251
4 actin related protein 2/3 complex subunit 5 16310 5.47 gi|5031593 3.32 ↓ 54%/259
5 enhancer of rudimentary homolog 12251 5.63 gi|4758302 14.3 ↓ 30%/211
6 S100 calcium-binding protein A4 11721 5.85 gi|4506765 5.22 ↓ 58%/276
(↓ stands for down-regulation; ↑ stands for up-regulation).
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by ischemia and is necessary for wound healing [12].
These studies suggest that Nogo-B may play a complex
role in different stages and types of inflammation. In
the case of airway remodeling of asthma, decreased
Nogo-B may also result from inflammation and a repair
response. A similar phenomenon was also observed in
both a mouse model of acute asthma and in severe asth-
matic patients [22]. In the next step, we are going to
construct the chronic asthma models of mice on Nogo-
B deficient mice and hope to find out the exact role of
Nogo-B on airway smooth muscle remodeling.
Nogo-B was originally identified as an apoptosis-indu-
cing protein through multiple pathways [23,24] and then
was know as a regulator of vascular remodeling [12].
As both proliferation and apoptosis are believed to con-
t r i b u t et oa i r w a ys m o o t hm u s c l er e m o d e l i n gi na s t h m a
[25], we tested whether Nogo-B played a role in airway
remodeling. We found that down-regulation of Nogo-B
had no effects on the proliferation of HBSMCs. Our
findings confirm the result of a previous investigation
demonstrating that stable transfectants overexpressing
Nogo-B did not differ significantly from the respective
parental wild-type of control cell lines both in respect to
cell proliferation and to spontaneous apoptosis induced
by staurosporine and tunicamycin [26]. These results
s u g g e s tt h a tN o g o - Bm a yn o te x e r ti t sr o l et h r o u g h
modulation on proliferation and apoptosis.
Increased emigration of airway smooth muscle cells
was also thought to participate in airway remodeling in
asthma [27]. We showed that down-regulation of Nogo-
B significantly inhibited PDGF-induced migration of
HBSMCs, underscoring a role for Nogo-B in airway
smooth muscle remodeling. Previous studies demon-
strated that Nogo-B played a complex role in cell migra-
tion. For example, Nogo-B N-terminal peptides promote
migration of endothelial cells while inhibiting migration
of vascular muscle cells [11], and Nogo-B deficient
macrophages exhibited deficiency in migration and
spreading [12]. Three mechanisms, besides different cell
lines, may account for such differences. Firstly, genomic
studies have revealed that Nogo-B deficient mice show
significantly decreased expression of Nogo-B receptors,
which are vital for chemotaxis and morphogenesis of
endothelial cells [12]. Secondly, PDGF receptors are
down-regulated after Nogo-B knock-down, which defi-
nitely attenuates the effects of PDGF-induced migration
[12]. Finally, we report for the first time that down-reg-
ulation of Nogo-B inhibites the expression of ARPC 2/3
subunit 5. ARPC 2/3 subunit 5 is a family member of
actin related protein complex 2/3 and plays an impor-
tant role in actin-filament nucleation, and ARPC 2/3
inhibition results in diminished migration [28,29]. Taken
together, these mechanisms also explain the inhibitory
effect on migration after Nogo-B knock-down in our
experiment.
Interestingly, we demonstrated for the first time that
Nogo-B knock-down may increased the contraction of
HBSMCs by up-regulating MYL-9. MYL-9, also know as
myosin light chain 2 (MLC-2), is a 20 kDa protein that
can be phosphorylated by myosin light chain kinase in
the presence of calcium and calmodulin and increases
the actin-activated ATPase activities of myosins [30].
Phosphorylation of MYL-9 initiates the contraction of
smooth muscle cells [31]. When it is up-regulated, more
contract-related proteins are recruited and the capability
and sensitivity of contraction is greatly enhanced. Our
results from proteomic analysis provide an exciting pos-
sible explanation of how Nogo-B modulating migration
and contraction. However, the precise mechanisms
deserve further investigation.
Conclusions
In conclusion, the present study implicates Nogo-B in
airway remodeling in asthma. Endogenous Nogo-B,
which may exert its effects through ARPC 2/3 and
MYL-9, is necessary for the migration and contraction
of airway smooth muscle cells. Further studies are
needed to clarify the therapeutic potential of Nogo-B
during airway remodeling in asthma.
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